ZDF German Television: From historical conflicts to family ties: New8 showcases second slate of international drama series
Following the success of the first series of New8, the new projects of this international drama collaboration of eight public broadcasters were presented today at Series Mania in Lille. The partners of New8 – SVT (Sweden), DR (Denmark), YLE (Finland), RÚV (Iceland), NRK (Norway), VRT (Flanders, Belgium), NPO (Netherlands) and ZDF (Germany) – have coproduced eight drama series since the start of the collaboration in autumn 2023. The aim of New8 is to coproduce high-quality series across national borders that reflect the values of public service media and appeal to a broad audience.
The projects selected for the second slate once again present an exciting variety of genres and topics. These range from historical and social drama series to family stories, crime series and mystery series:
"Breendonk"(VRT, Belgium, 6x54 minutes), "Phoenix" (ZDF, Germany, 6x45 minutes), "The Machine", (NPO/BNNVARA, The Netherlands, 6x54 minutes), "Henki" (NRK, Norway, 6x45 minutes), "Cold Song" (SVT, Sweden, 6x45 minutes), "Generations" (DR, Denmark, 6x60 minutes), "Death of a Horse" (RÚV, Iceland, 6x52 minutes) and "The Dark Ones" (ZDF, Germany, 6x45 minutes).
The first eight series of the coproduction initiative have been already produced: "Vanguard" (SVT), "Elixir" (NPO), "Queen of fucking everything" (YLE), "Holmlia Love" (NRK), "Other People's Money" (DR/ZDF), "This is not a murder mystery" (VRT), "Push" and "Kabul" (ZDF). Some of them have already been honoured nationally and internationally. These include ZDF's New8 series "Push" (German Television Award 2024) and ‘"Kabul" (Series Mania 2025 – International Competition), as well as "Other People's Money" (Berlinale 2025 - Panorama section) and "Generations" (Series Mania 2025 – International Competition), both of which were brought into the cooperation by the Danish broadcaster DR.
The programs in detail and more Information.
Kontakt: ZDF-Kommunikation, pressedesk@zdf.de
Follow us LinkedIn.
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 15:16:10 CET | Press release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
VORN Bioenergy announces appointments to leadership team15.1.2026 11:14:45 CET | Press release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom